ClinConnect ClinConnect Logo
Search / Trial NCT06890260

The Treatment of Moderate to Severe Allergic Rhinitis With Electroacupuncture Combined With Microneedle Knife

Launched by PENGFEI QIU · Mar 16, 2025

Trial Information

Current as of April 29, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying a new way to treat moderate to severe allergic rhinitis, commonly known as hay fever. The treatment combines two methods: electroacupuncture, which uses small electrical currents to stimulate specific points on the body, and a microneedle knife, which is a tool that creates tiny, controlled wounds to help improve symptoms. Participants in the trial will be compared with a control group receiving standard medications like cetirizine (an antihistamine) and budesonide (a nasal spray). The goal is to see which treatment works better in reducing nasal symptoms and improving quality of life for those suffering from allergic rhinitis.

To be eligible for the trial, participants must be between 18 and 75 years old and have a confirmed diagnosis of moderate to severe allergic rhinitis. They should not have taken any antihistamines or nasal steroids in the month before joining the study and must agree to attend outpatient appointments for four weeks. Throughout the trial, participants will be monitored at different intervals to assess their symptoms and overall health. This is an important opportunity for people who are struggling with allergies to potentially find relief through new treatment options.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Those with clinical and laboratory diagnosis of moderate to severe allergic rhinitis;
  • 2. Aged ≥18 years and ≤75 years, with no restriction on gender or ethnicity;
  • 3. Not taking drugs such as antihistamines or nasal steroids within 1 month before enrollment;
  • 4. Those who voluntarily participated in this study and signed an informed consent form, and who were able to adhere to outpatient treatment for 4 weeks.
  • Exclusion Criteria:
  • 1. Atrophic rhinitis, hypertrophic rhinitis, vasomotor rhinitis, acute and chronic sinusitis, nasal polyps, severe septal deviation, eosinophilia non-allergic rhinitis;
  • 2. Those with other allergic diseases such as asthma, urticaria, and colds that cause nasal congestion, runny nose, and sneezing;
  • 3. Those who have serious diseases such as cardiovascular, cerebrovascular, hepatic, renal and hematopoietic systems in combination;
  • 4. Pregnant or lactating women, psychiatric patients, patients with malignant tumors.

About Pengfei Qiu

Pengfei Qiu is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and improving patient outcomes. With a focus on innovative therapeutic solutions, Pengfei Qiu collaborates with leading research institutions and healthcare professionals to design and conduct rigorous clinical trials. His expertise spans various therapeutic areas, emphasizing a patient-centered approach and adherence to regulatory standards. Through strategic partnerships and a commitment to scientific integrity, Pengfei Qiu aims to contribute meaningful advancements in healthcare and enhance the quality of life for patients worldwide.

Locations

Hangzhou City, Zhejiang, China

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported